Volume 9, Number 3—March 2003
Dispatch
Persistence of Virus-Reactive Serum Immunoglobulin M Antibody in Confirmed West Nile Virus Encephalitis Cases
Table 2
Number WNV IgM positive/total (%) |
|||||
---|---|---|---|---|---|
Acute
(n=27) |
3 months
(n=15) |
6 months
(n=23) |
9 months
(n=23) |
12 months
(n=18) |
|
Age |
|||||
<65 yrs |
9/9 (100) |
6/6 (100) |
6/9 (67) |
4/8 (50) |
0/5 (0) |
+65 yrs |
18/18 (100) |
9/9 (100) |
9/14 (64) |
5/15 (33) |
2/13 (15) |
Sex |
|||||
Male |
13/13 (100) |
8/8 (100) |
8/11 (73) |
3/10 (30) |
1/9 (11) |
Female |
14/14 (100) |
7/7 (100) |
7/12 (58) |
6/13 (46) |
1/9 (11) |
Clinical syndrome |
|||||
Encephalitis |
16/16 (100) |
8/8 (100) |
8/13 (62) |
5/13 (39) |
2/11 (18) |
Meningitis |
11/11 (100) |
7/7 (100) |
7/10 (70) |
4/10 (40) |
0/7 (0) |
Baseline IgMb |
|||||
<Median P/N |
14/14 (100) |
6/6 (100) |
6/11 (55) |
3/12 (25) |
0/10 (0) |
>median P/N | 13/13 (100) | 9/9 (100) | 9/12 (75) | 6/11 (55) | 2/8 (25) |
aWNV, West Nile virus; Ig, immunoglobulin; P/N, positive-to-negative; P/N ratio > 3.0.
bMedian P/N = 11.4.
Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.